Summer 2010 Lyme Times Table of Contents - the definitive voice on Lyme disease.

Lyme Guidelines: Treatment Choice Essential for Patient-Centered Care

Advocate admonishes panel to recognize global science and prevent harm from treatment and insurance denials

By Tina Garcia

Lyme Guidelines: IDSA’s Rigid Position Limits Treatment Options

Guidelines should acknowledge legitimate scientific controversy and allow clinical discretion

By Lorraine Johnson, JD, MBA

Lyme Guidelines: IDSA’s Practice Guidelines Miss the Evidence Mark

Clinical expertise and patient values should frame future guidelines

By Daniel Cameron, MD, MPH

Lyme Guidelines: Research Confirms Persistent Infection

Animal and human trials hold clues to effective treatments Presented

By Ben Luft, MD

Lyme Guidelines: Focus on the Evidence

Guidelines should reflect what we know (and don’t know)

By David Volkman, MD, PhD

Lyme Guidelines: “Post-Treatment” Lyme a Misnomer

Patient trials and test results suggest better treatment approaches

By Sam Donta, MD

Lyme Guidelines: Debunking Doubts about Antibiotic Efficacy

Clinical experience and risk-benefit review raise importance of informed consent

By Brian Fallon, MD, MPH, MEd

Lyme Guidelines: Critical Care Experience Informs Treatment Protocols

Survey of patient cases supports long-term antibiotic therapy

By Ken Liegner, MD

Lyme Guidelines: Documenting Persistent Infection

ILADS past-president presents evidence challenging IDSA recommendations

By Steven Phillips, MD

Lyme Guidelines: Objections to Requirements and Restrictions

LLMD criticizes IDSA conclusions on diagnostic testing, clinical judgment, persistent infection, treatment options

By Raphael Stricker, MD

Biostatistician Disputes IDSA Guideline Conclusions

An Interview With Allison DeLong

By Lyme Times Staff

Scrutinizing the Scientific Evidence

Statistical analysis of treatment trials reveals inadequate justification for restricting clinical discretion

By Elizabeth Maloney, MD